drugset / Trial / NCT00005762

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

NCT00005762

Treatment

Summary

The purpose of this study is to measure the blood levels of amprenavir (APV) alone, APV combined with efavirenz (EFV), and APV/EFV combined with a third drug (nelfinavir \[NFV\], indinavir \[IDV\], ritonavir soft gel capsules \[RTV sgc\], or saquinavir soft gel capsules \[SQV sgc\]). Anti-HIV therapy with 3 or 4 drugs is currently the recommended approach for treating HIV infections. Doctors need to know the best dosages of certain drugs when they are given in combination. This study will measure the blood levels of APV alone, APV combined with EFV, and APV/EFV plus a second PI in healthy volunteers. It will study the safety and tolerance of these drugs.

Timeline

Start
2001-03
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Amprenavir Other / unclassified
Subject Efavirenz Other / unclassified 600 mg
Subject INDINAVIR ANHYDROUS Other / unclassified 1200 mg
Subject Nelfinavir Other / unclassified 1250 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Saquinavir Small molecule 1600 mg